



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 December 2021
EMA/115282/2012-Rev.1
Veterinary Medicines and Product Data Management

Framework for a correlation table (VNeS:CTD) for ASMFs/Part 2 in CTD format for dossiers for veterinary medicinal products

The following table is only a framework for an acceptable correlation table. Other types of correlation tables and other more detailed subheadings may also be acceptable.

As the VNeS and CTD formats have completely different chapters/sections, and not similar ones, it is very difficult to give a definitive comparative list. Furthermore, the dossier structure will vary depending on several factors such as the type of product, number and type of active substance(s), etc.

The table below shows the headings from the current legislation Annex II of Regulation (EU) 2019/6 as amended by Commission Delegated Regulation (EU) 2021/805.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact

Telephone +31 (0)88 781 6000

An agency of the European Union



VNees	VNees headings (from legislation)	EU CTD	CTD
---	---	MODULE 3 TABLE OF CONTENTS	3.1
Part 2	QUALITY DOCUMENTATION (PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL INFORMATION)	BODY OF DATA	3.2
2.A	PRODUCT DESCRIPTION		
2.A.1	Qualitative and quantitative composition	Description and composition of the drug product	3.2.P.1
2.A.2	Product Development	Pharmaceutical Development	3.2.P.2
2.B	DESCRIPTION OF THE MANUFACTURING METHOD	Manufacture	3.2.P.3
		Manufacturer(s)	3.2.P.3.1
		Batch formula	3.2.P.3.2
		Description of Manufacturing Process and Process Controls	3.2.P.3.3
		Facilities and Equipment	3.2.A.1
		Controls of critical steps and intermediates	3.2.P.3.4
		Process validation and/or evaluation	3.2.P.3.5
2.C	PRODUCTION AND CONTROL OF STARTING MATERIALS		
2.C.1.	Active substances	DRUG SUBSTANCE	3.2.S
2.C.1.1.	Active substances listed in pharmacopoeias		
2.C.1.2	Active substances not in a pharmacopoeia		
		General Information	3.2.S.1
		Nomenclature	3.2.S.1.1
		Structure Description:	3.2.S.1.2
		General Properties	3.2.S.1.3
		Manufacture	3.2.S.2
		Manufacturer(s)	3.2.S.2.1
		Description of manufacturing process and process controls	3.2.S.2.2
		Control of materials	3.2.S.2.3
		Controls of critical steps and intermediates	3.2.S.2.4
		Process validation and/or evaluation	3.2.S.2.5
		Manufacturing process development	3.2.S.2.6
		Characterisation	3.2.S.3
		Elucidation of structure and other characteristics	3.2.S.3.1
		Impurities	3.2.S.3.2
		Control of drug substance	3.2.S.4
		Specification	3.2.S.4.1
		Analytical Procedures	3.2.S.4.2
		Validation of analytical procedures	3.2.S.4.3
		Batch analyses	3.2.S.4.4

VNees	VNees headings (from legislation)	EU CTD	CTD
		Justification of Specification	3.2.S.4.5
		Reference Standards or Materials	3.2.S.5
2.C.1.3	Physicochemical characteristics liable to affect bioavailability		
2.C.2	Excipients	Control of excipients	3.2.P.4
2.C.3	Packaging (container-closure systems)		
2.C.3.1	Active substance	Container Closure System	3.2.S.6
2.C.3.2	Finished Product	Container Closure System	3.2.P.7
2.C.4	Substances of biological origin	Adventitious Agents Safety Evaluation	3.2.A.2
		Excipients of human or animal origin	3.2.P.4.5
2.D	CONTROL TESTS CARRIED OUT ON ISOLATED INTERMEDIATES DURING THE MANUFACTURING PROCESS	Controls of critical steps and intermediates	3.2.P.3.4
2.E	CONTROL TESTS ON THE FINISHED PRODUCT	Control of drug product	3.2.P.5
2.E.1	General characteristics of the finished product	Specification(s)	3.2.P.5.1
		Justification of specification(s)	3.2.P.5.6
		Characterisation of Impurities	3.2.P.5.5
		Analytical Procedures	3.2.P.5.2
2.E.2	Identification and assay of active substance(s)	Validation of Analytical Procedures	3.2.P.5.3
		Reference Standards or Materials	3.2.P.6
2.E.3	Identification and assay of excipient components	Validation of Analytical Procedures	3.2.P.5.3
		Reference Standards or Materials	3.2.P.6
2.E.4	Microbiological controls		
2.E.5	Batch-to-batch consistency	Batch analyses	3.2.P.5.4
2.E.6	Other controls		
2.F	STABILITY TESTS		
2.F.1	Active substances	Stability	3.2.S.7
2.F.2	Finished Product	Stability	3.2.P.8
2.G	OTHER INFORMATION		
	<i>Post Approval Change Management Protocols (new)</i>		
		APPENDICES	3.2.A
		LITERATURE REFERENCES	3.3